Beyond Air to Participate in the 38th Annual Roth Conference in March
Rhea-AI Summary
Beyond Air (NASDAQ: XAIR) announced that CEO Steve Lisi will participate in the 38th Annual Roth Conference in Laguna Niguel, CA, March 22–24, 2026.
Steve Lisi will appear for a fireside chat and one-on-one meetings on Monday, March 23 at 8:00am PT. A live webcast is available and an archive will be posted for 90 days after the event. Investors seeking a one-on-one should contact their bank representative to request a meeting.
Positive
- None.
Negative
- None.
News Market Reaction – XAIR
In the Mar 11 session, XAIR declined 2.57%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 10 | Deal termination | Negative | -4.0% | Termination of proposed NeuroNOS sale after LOI expiration without definitive deal. |
| Feb 20 | Clinical commentary | Positive | -7.3% | Company highlighted independent review of 27 high‑dose nitric oxide studies. |
| Feb 13 | Earnings update | Positive | +2.9% | Reported Q3 2026 results with 105% YoY revenue growth and maintained guidance. |
| Feb 04 | Clinical trial data | Positive | -5.2% | Selection to present Phase 1 UNO solid tumor data at AACR 2026 meeting. |
| Jan 27 | Conference participation | Neutral | -5.9% | Announcement of participation in two early‑February healthcare investor conferences. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has often been followed by negative moves, even on seemingly positive clinical and corporate updates, with only the latest earnings showing a positive reaction.
Over the last few months, XAIR has released a mix of corporate, clinical, and financing updates. Earnings on Feb 13, 2026 showed strong revenue growth and a narrower net loss, and that announcement drew a modest positive reaction of +2.94%. By contrast, clinically oriented updates and conference participation on Feb 4, 2026 and Jan 27, 2026 saw shares decline between 5–6%. The March 10 termination of the NeuroNOS sale letter of intent also preceded a 4.02% drop, framing today’s Roth conference news against a backdrop of weakness.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GARDEN CITY, N.Y., March 11, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman & Chief Executive Officer of Beyond Air, will participate in the 38th Annual Roth Conference being held March 22nd to 24th in Laguna Niguel, CA.
| 38th Annual Roth Conference | |
| Format: | Fireside chat and one-on-one meetings |
| Presentation Date: | Monday, March 23 at 8:00am PT |
| Participant: | Steve Lisi, Chairman & Chief Executive Officer of Beyond Air |
| Live Webcast Link: | https://event.summitcast.com/view/kKmFFrbEes9oUCyrRFmQ5N/guest_book?session_id=LxtopFpYTZL68pJiouzW2f |
If you are interested in requesting a one-on-one meeting at the conference, please contact your bank representative to schedule accordingly.
An archive of the webcast will be available at https://www.beyondair.net/news-events/events for 90 days following the event.
About Beyond Air®, Inc.
Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria (NTM).
Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net.
CONTACTS:
Investor Relations contacts
Corey Davis, Ph.D.
LifeSci Advisors, LLC
Cdavis@lifesciadvisors.com
(212) 915-2577
